A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation

Transplantation
R W GruessnerA C Gruessner

Abstract

Between May 1, 1993 and April 5, 1995, 154 pancreas allograft recipients at 9 institutions were given FK506 posttransplant. Three groups were studied: (1) recipients given FK506 initially for induction and maintenance therapy (n = 82), (2) recipients switched to FK506 for antirejection or rescue therapy (n = 61), and (3) recipients converted to FK506 for other reasons (n = 11). Of 82 patients in the induction group, 7 (9%) had simultaneous bone marrow (BM) and pancreas-kidney (SPK-BM) transplants, 54 (66%) had SPK transplants without BM, 14 (17%) had pancreas transplants alone (PTA), and 7 (9%) had pancreas after previous kidney transplants (PAK). All but 1 recipient was given quadruple immunosuppression (anti-T cell agents plus azathioprine and prednisone) for induction. The median FK506 starting dose was 4 mg/day p.o.; the median average FK506 blood level, 12 ng/ml. The most common side effects were neurotoxicity (16%), nephrotoxicity (13%), and gastrointestinal toxicity (9%). New-onset diabetes mellitus requiring permanent insulin therapy did not occur. Of 61 transplants in the rescue group, 44 (72%) were SPK, 11 (18%) PTA, and 6 (10%) PAK. All but 3 (95%) of the recipients had been on cyclosporine-azathioprine-prednisone tr...Continue Reading

References

Mar 27, 1994·Transplantation·S TodoA J Demetris
Aug 15, 1994·Transplantation·R M JindalC M Miller
Oct 27, 1994·The New England Journal of Medicine·UNKNOWN U.S. Multicenter FK506 Liver Study Group
Oct 1, 1993·Transplantation·J Tabasco-MinguillanT E Starzl

❮ Previous
Next ❯

Citations

Nov 15, 2002·International Journal of Hematology·Jean E Sanders
Apr 21, 2004·Pancreas·Spiros DelisGaetano Ciancio
Nov 14, 1997·Annals of Surgery·R W GruessnerD E Sutherland
Feb 16, 2000·Annals of Surgery·A HumarD E Sutherland
Sep 24, 1998·Transplantation Proceedings·S FornaironC Legendre
Jun 24, 1998·Transplantation Proceedings·R W Gruessner
May 29, 2012·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Shaneel R Patel, Nadey Hakim
Aug 1, 1997·Journal of the American College of Surgeons·R W GruessnerA C Gruessner
Sep 27, 2014·Expert Opinion on Drug Metabolism & Toxicology·Erika B Rangel
Mar 16, 2001·Expert Opinion on Pharmacotherapy·G CiancioJ Miller
May 1, 1997·The American Journal of the Medical Sciences·P F Halloran
Oct 3, 1999·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·E LetkoA R Ahmed
Jan 12, 2000·Mayo Clinic Proceedings·M D StegallR A Rizza
Mar 1, 2008·Journal of the American College of Surgeons·Rainer W G GruessnerAngelika C Gruessner
Oct 11, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Nicolas DemartinesPierre-Alain Clavien
Nov 15, 2006·Clinical Transplantation·B M SchmiedJ Schmidt
Aug 21, 2008·Transplant International : Official Journal of the European Society for Organ Transplantation·Diego Cantarovich, Fabio Vistoli
Aug 5, 2009·Journal of Hepato-biliary-pancreatic Sciences·Jason F ReynosoRainer W G Gruessner
Jun 1, 1997·Surgery·N S HakimR W Gruessner
Apr 28, 2004·Transplantation Proceedings·U BoggiF Mosca
Mar 31, 2004·Journal of the American College of Surgeons·Rainer W G GruessnerAngelika C Gruessner
Jan 18, 2006·Advances in Chronic Kidney Disease·David Williams, Lukas Haragsim
Jan 3, 2006·Transplantation Proceedings·J Nicoluzzi
Dec 12, 2012·Expert Opinion on Pharmacotherapy·Thomas Rath
Nov 21, 1997·Transplantation Proceedings·L Rosenberg
Jan 1, 1997·Transplant International : Official Journal of the European Society for Organ Transplantation·G BeckerU Heemann
Jun 1, 2000·Clinical Transplantation·R M Jindal, J M Dubernard
Aug 13, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·S A WhiteN J London
Jul 9, 1999·Hospital Medicine·C C MageeE L Milford
Jun 18, 2004·Transplantation·George W BurkeHans W Sollinger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.